Ault Milton C III's Form 4/A amendment
AmendedAlzamend Neuro, Inc. (ALZN) · filed Aug 31, 2026
- Accession no.
- 0001214659-26-011110
- Filed
- Aug 31, 2026, 6:00 AM ET
- Trade date
- Apr 14, 2026
- Filing delay
- 139 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Apr 16, 2026
This filing lists 2 non-derivative transactions. Open-market purchases total $111.0K. It was filed 139 days after the trade.
This filing was later replaced by the amendment 0001214659-26-011111 (Aug 31, 2026). Trade tables on this site use the amended version.
This amendment replaces 0001214659-26-004742 (filed Apr 16, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ault Milton C IIICIK 0001212502 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | Common Stock | PPurchaseAcquired | +108,388 | $1.00 | +$108,897.42 | 116,648 | Indirect | |
| Apr 14, 2026 | Common Stock | PPurchaseAcquired | +2,000 | $1.03F2 | +$2,067.6 | 2,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Milton C. Ault, III, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
- F2
The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.0338. The range of purchase prices on the transaction date was $1.00 to $1.05 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
Referenced by the price of 1 transaction in Table I.
- F3
Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
- F4
Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
Remarks
The original Form 4 filed on April 16, 2026 (the "Original Filing") is amended by this Form 4/A solely to report shares of common stock purchased by the reporting person that were inadvertently omitted from the Original Filing. Other than the correction reflected herein, no changes have been made to the transactions or holdings previously reported in the Original Filing.